Preclinical studies have shown that SB-3CT, a more selective inhibitor targeting MMP-2 and MMP-9, can reduce infarct size and preserve BBB integrity in animal models of ischemic stroke (Cai et al., 2017). The gene discussed is MMP9; the disease is ischemic stroke.